UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022582
Receipt number R000025854
Scientific Title Examination of efficacy and safety of oral cryotherapy to prevent oral mucositis due to chemotherapy in breast cancer patients
Date of disclosure of the study information 2016/06/10
Last modified on 2019/05/30 13:37:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination of efficacy and safety of oral cryotherapy to prevent oral mucositis due to chemotherapy in breast cancer patients

Acronym

Examination of efficacy and safety of oral cryotherapy to prevent oral mucositis due to chemotherapy in breast cancer patients

Scientific Title

Examination of efficacy and safety of oral cryotherapy to prevent oral mucositis due to chemotherapy in breast cancer patients

Scientific Title:Acronym

Examination of efficacy and safety of oral cryotherapy to prevent oral mucositis due to chemotherapy in breast cancer patients

Region

Japan


Condition

Condition

breast cancer

Classification by specialty

Hepato-biliary-pancreatic medicine Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To explore efficacy and safety of oral cryotherapy to prevent oral mucositis due to chemotherapy in breast cancer patients

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Rate of all grade oral mucositis

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Other

Interventions/Control_1

oral cryotherapy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1. The patients who had a diagnosis of invasive breast cancer by needle biopsy or tissue biopsy
2. FEC(EC)100/TC therapy enforcement planned patients
3. The patients who do not receive previous treatment for breast cancer
4. The patients who do not have oral mucositis before treatment
5. The patients without inadequate dentures
6. The patients that PS is 0-1
7. Age is women 80 years or younger 20 years old or older at the time of the agreement acquisition
8. The patients having more than 55% of left ventricular ejection fractions (LVEF) in an echocardiography
9. The patients without the abnormality clinical in an electrocardiogram
10. The patients that an agreement was obtained in a document

Key exclusion criteria

1. Advanced or metastatic breast cancer
2. A pregnant woman and the patients who may be pregnant or the patients whom we are nursing
3. The patients whom a study person in charge judged to be inadequate as study patients

Target sample size

58


Research contact person

Name of lead principal investigator

1st name Eguchi
Middle name
Last name Susumu

Organization

Nagasaki University Graduate School of Biomedical Science

Division name

Surgery

Zip code

852-8501

Address

1-17-1, Sakamoto-machi

TEL

095-849-7316

Email

sueguchi@nagasaki-u.ac.jp


Public contact

Name of contact person

1st name Kuba
Middle name
Last name Sayaka

Organization

Nagasaki University Graduate School of Biomedical Science

Division name

Surgery

Zip code

852-8501

Address

1-7-1, Sakamoto-machi, Nagasaki city

TEL

095-849-7316

Homepage URL


Email

skuba@nagasaki-u.ac.jp


Sponsor or person

Institute

Nagasaki University Graduate School of Biomedical Science

Institute

Department

Personal name



Funding Source

Organization

Nagasaki University Graduate School of Biomedical Science

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB

Address

Sakamoto-machi

Tel

095-819-7726

Email

no


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 06 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2015 Year 12 Month 01 Day

Date of IRB

2016 Year 03 Month 20 Day

Anticipated trial start date

2016 Year 04 Month 01 Day

Last follow-up date

2018 Year 04 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 06 Month 02 Day

Last modified on

2019 Year 05 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025854


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name